Mesoblast (ASX:MSB) Valuation Check As Leadership Changes And Debt Refinancing Reset Expectations

Simply Wall St.01-09

Mesoblast (ASX:MSB) is back in focus after a cluster of late December and early January announcements, including new board leadership, fresh credit arrangements with an existing director, and sizable ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602729863?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-09 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602729863","market":"nz","top_or_hot":-1,"title":"Mesoblast (ASX:MSB) Valuation Check As Leadership Changes And Debt Refinancing Reset Expectations","media":"Simply Wall St.","content":"<div>\n<p>Mesoblast (ASX:MSB) is back in focus after a cluster of late December and early January announcements, including new board leadership, fresh credit arrangements with an existing director, and sizable ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-leadership-changes-and-d\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast (ASX:MSB) Valuation Check As Leadership Changes And Debt Refinancing Reset Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast (ASX:MSB) Valuation Check As Leadership Changes And Debt Refinancing Reset Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 17:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-leadership-changes-and-d><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mesoblast (ASX:MSB) is back in focus after a cluster of late December and early January announcements, including new board leadership, fresh credit arrangements with an existing director, and sizable ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-leadership-changes-and-d\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-leadership-changes-and-d","article_id":"2602729863","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-leadership-changes-and-d","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602729863","pubTimestamp":1767951288,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Mesoblast (ASX:MSB) is back in focus after a cluster of late December and early January announcements, including new board leadership, fresh credit arrangements with an existing director, and sizable shelf registrations in both ordinary shares and ADSs.\nSee our latest analysis for Mesoblast.\nThe recent board reshuffle, fresh credit facility and large shelf registrations appear to have caught the market’s eye, with a 1-day share price return of 4.07% and a 7-day share price return of 10.83%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","MSB.AU":"MESOBLAST LTD","BK7508":"医药生物股","BK7501":"新冠治疗股","BK4006":"钢铁","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","MSB":"美莎比信托"},"translate_title":"随着领导层变动和债务再融资重置预期，Mesoblast(ASX：MSB)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB":1.5,"DCF":1,"MSB.AU":1.5},"content_text":"Mesoblast (ASX:MSB) is back in focus after a cluster of late December and early January announcements, including new board leadership, fresh credit arrangements with an existing director, and sizable shelf registrations in both ordinary shares and ADSs. See our latest analysis for Mesoblast. The recent board reshuffle, fresh credit facility and large shelf registrations appear to have caught the market’s eye, with a 1-day share price return of 4.07% and a 7-day share price return of 10.83%. The 3-year total shareholder return of roughly 2.5x suggests momentum has been building over a longer stretch. If Mesoblast’s recent moves have you looking more broadly across healthcare, it could be a good moment to scan healthcare stocks for other companies reshaping their future. With Mesoblast trading at A$3.07, a roughly 23% gap to the A$3.78 analyst target and an intrinsic value estimate implying a large discount, you have to ask: is there still upside here, or is the market already baking in future growth? AdvertisementPrice-to-Book of 4.4x: Is it justified? On a P/B of 4.4x at A$3.07, Mesoblast screens as cheaper than many peers, which hints at some market skepticism despite recent share price strength. P/B compares the market value of the company to its net assets, which matters for a biotech like Mesoblast that is still loss making but asset rich in intellectual property and R&D. Here, Mesoblast’s 4.4x P/B sits below both the Australian biotechs industry average of 6x and the peer average of 4.7x. This suggests investors are assigning a lower premium to its balance sheet and pipeline than they are to comparable names. That discount looks even starker beside the SWS DCF fair value estimate of A$26.09 per share, which is very large compared to the current A$3.07 price and implies the market is pricing in much more cautious long term outcomes than the cash flow model. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of 4.4x (UNDERVALUED) However, you still have to weigh clinical trial outcomes and Mesoblast’s current A$102.142 million net loss, either of which could quickly change the market’s stance. Find out about the key risks to this Mesoblast narrative. Another way to look at value If the 4.4x P/B leaves you thinking Mesoblast is only modestly mispriced, our DCF model presents a very different perspective. With a fair value estimate of A$26.09 versus the current A$3.07 share price, the implied discount appears very large. This raises a simple question: is the model too optimistic or is the market too cautious? Look into how the SWS DCF model arrives at its fair value. MSB Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Mesoblast for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 871 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Mesoblast Narrative If you see the numbers differently or want to stress test your own assumptions against the data, you can build a personalised Mesoblast view in just a few minutes, starting with Do it your way. A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Mesoblast. Looking for more investment ideas? If Mesoblast has sharpened your thinking, do not stop here. Use carefully filtered stock ideas to pressure test your portfolio and spot opportunities others might miss.  Target potential mispricings by scanning these 871 undervalued stocks based on cash flows that could offer more compelling value than the usual large cap names everyone already watches. Ride structural shifts in technology by checking out these 28 AI penny stocks that are tied to real business models rather than just hype. Boost your income watchlist by reviewing these 11 dividend stocks with yields > 3% that already carry yields above 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602729863","isCrawlerRequest":true}